NCT06961630View on ClinicalTrials.gov

Post-Operative Biomarker-Guided Precision Medicine For Cardiovascular Risk Reduction

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

October 7, 2025

Primary Completion Date

March 31, 2027

Study Completion Date

March 31, 2027

Conditions
Myocardial Injury After Noncardiac Surgery
Interventions
DRUG

Rivaroxaban

Rivaroxaban 2.5mg will be orally administered twice daily for 6 months.

DRUG

Atorvastatin

Atorvastatin 80mg will be orally administered daily for 6 months.

Trial Locations (1)

10016

RECRUITING

NYU Langone Health, New York

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

NYU Langone Health

OTHER